ProQR Doses First Patient in Phase 1/2 STELLAR Trial of QR-421a for Usher Syndrome Type 2

Original text here LEIDEN, Netherlands and CAMBRIDGE, Mass., March 11, 2019 (GLOBE NEWSWIRE) — ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the first patient dosed in the Phase 1/2 STELLAR clinical trial for QR-421a in patients with Usher syndrome type 2 or non-syndromic retinitis pigmentosa (RP).
Read

International Symposium on Usher Syndrome 2018

Last week the International Symposium on Usher Syndrome was held in Mainz. It was a 3-day event, we only attended the patient’s symposium as I was afraid that the 2 scientific days would be too complicated to follow anyway (and I would be braindead before the patient program even started…).
Read

NoisyVision is ambassador for DiseaseMaps

In this post a few months ago we wanted to stretch the importance to participate in the DiseaseMaps project, emphasizing its mission We connect people who are suffering from different conditions to help them finding things to make their lives better Today we are proud to annouce we are ambassador for Usher Syndrome on the DiseaseMap In other words we will give concrete support to the project, helping in the dissemination of the maps, in particular those of the Usher Syndrome and Retinitis Pigmentosa.
Read